AGE AgeX Therapeutics

AgeX Therapeutics, Inc. Announces That Its Annual Meeting of Stockholders Will Be Conducted Online Only

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE) announced today that due to state and county government health orders, attendance at the AgeX 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to be held at 10:00 a.m. Pacific Standard Time on Monday, December 28, 2020 will be permitted only through online participation. The County of Alameda, California, where AgeX’s offices are located and where AgeX had planned to hold the Annual Meeting, has issued Health Officer Order 20-21 (the “Order”) restricting or prohibiting many business activities due to the COVID-19 pandemic. The Order provides that offices must close and business must be conducted remotely, except in critical infrastructure sectors where remote work is not possible.

As disclosed in AgeX’s Proxy Statement, AgeX has made arrangements for stockholders to attend and vote at the Annual Meeting online. Stockholders who follow the procedures for attending the Annual Meeting online will be able to vote at the Annual Meeting and ask questions. If you do not comply with the procedures for attending the Annual Meeting online, you will not be able to participate and vote at the Annual Meeting online but you may view the Annual Meeting webcast by visiting and following the instructions to log in as a guest using the password agex2020.

If you are a “stockholder of record” (meaning that you have a stock certificate registered in your own name), to attend and participate in the Annual Meeting online you will need to visit and use the control number on your proxy card to log on. The password for the Annual Meeting is agex2020.

If you are a “street name” stockholder (meaning that your shares are held in an account at a broker-dealer firm) and you wish to participate and vote online at the Annual Meeting, you must first obtain a valid legal proxy from your broker, bank or other agent and then register in advance to attend the Annual Meeting by following the directions for registration in section of AgeX’s Proxy Statement entitled “HOW TO ATTEND THE ANNUAL MEETING”.

Please refer to your copy of the Proxy Statement for the Annual Meeting for other information about the Annual Meeting and matters proposed to be approved by AgeX stockholders at the Annual Meeting. A copy of the Proxy Statement and other proxy materials and our Annual Report on Form 10-K, as amended, can also be found at and on the SEC’s website at and in the “Investors-Financial Information-SEC Filings” portion of AgeX’s website at .

If you cannot participate online you may still vote your shares by submitting a proxy by mail, by phone, or online by following the instructions on your proxy card.

EN
22/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AgeX Therapeutics

 PRESS RELEASE

Serina Therapeutics Reports Second Quarter 2025 Financial Results and ...

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the second quarter ended June 30, 2025, along with key recent updates. “We’re proud of the momentum we’ve built across our development programs. With SER-252 on ...

 PRESS RELEASE

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive D...

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD) - Novel once-weekly injectable VMAT2 inhibitor targets underserved patients with serious adherence and access challenges – - Potential expansion into Huntington’s chorea – an underserved indication with high need for long-acting VMAT2 therapy - HUNTSVILLE, AL, July 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the advancement of its nove...

 PRESS RELEASE

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Confe...

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference HUNTSVILLE, AL, July 28, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that Steve Ledger, Chief Executive Officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference, taking place July 29-30, 2025. The discussion will be held on Tuesday, July 29, 2025, at 2:00 p.m. ET. About Serina Therapeutics Serina is a clinical-stage ...

 PRESS RELEASE

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan HUNTSVILLE, AL, July 10, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, announced that it has made a grant of options to purchase an aggregate of 12,500 shares of Serina’s common stock to a new non-executive employee on June 18, 2025 (the “Option Grant”). The Option Grant has an exercise price equal t...

 PRESS RELEASE

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meetin...

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting HUNTSVILLE, July 01, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced that its Board of Directors has established November 7, 2025, as the date of its 2025 annual meeting of stockholders (the “Annual Meeting”). The time and location of the Annual Meeting will be set forth in the Serina’s definitive proxy statement for the Annual Meeting to be filed with the Securities and Exchange Commission (the “SEC”). Because the date of the...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch